Listas | Seção | Observação |
---|---|---|
Peru | 05. Anticonvulsants/Antiepileptics | Sem observações |
Training CSamouge 2022 | 5. ANTICONVULSANTS/ ANTIEPILEPTICS |
Outras observações: For use as adjunctive therapy for treatment-resistant partial or generalized seizures. |
WHO Model List of Essential Medicines (2021) | 05. ANTICONVULSANTS/ ANTIEPILEPTICS |
Outras observações: For use as adjunctive therapy for treatment-resistant partial or generalized seizures. |
Listas | Seção | Observação |
---|---|---|
Cuba | 05. ANTICONVULSIVOS | Sem observações |
Training CSamouge 2022 | 5. ANTICONVULSANTS/ ANTIEPILEPTICS |
Outras observações: For use as adjunctive therapy for treatment-resistant partial or generalized seizures. |
WHO Model List of Essential Medicines (2021) | 05. ANTICONVULSANTS/ ANTIEPILEPTICS |
Outras observações: For use as adjunctive therapy for treatment-resistant partial or generalized seizures. |
Listas | Seção | Observação |
---|---|---|
Training CSamouge 2022 | 5. ANTICONVULSANTS/ ANTIEPILEPTICS |
Outras observações: For use as adjunctive therapy for treatment-resistant partial or generalized seizures. |
WHO Model List of Essential Medicines (2021) | 05. ANTICONVULSANTS/ ANTIEPILEPTICS |
Outras observações: For use as adjunctive therapy for treatment-resistant partial or generalized seizures. |
Listas | Seção | Observação |
---|---|---|
Training CSamouge 2022 | 5. ANTICONVULSANTS/ ANTIEPILEPTICS |
Outras observações: For use as adjunctive therapy for treatment-resistant partial or generalized seizures. |
WHO Model List of Essential Medicines (2021) | 05. ANTICONVULSANTS/ ANTIEPILEPTICS |
Outras observações: For use as adjunctive therapy for treatment-resistant partial or generalized seizures. |
Listas | Seção | Observação |
---|---|---|
Training CSamouge 2022 | 5. ANTICONVULSANTS/ ANTIEPILEPTICS |
Outras observações: For use as adjunctive therapy for treatment-resistant partial or generalized seizures |
WHO Model List of Essential Medicines (2021) | 05. ANTICONVULSANTS/ ANTIEPILEPTICS |
Outras observações: For use as adjunctive therapy for treatment-resistant partial or generalized seizures. |
Listas | Seção | Observação |
---|---|---|
Training CSamouge 2022 | 5. ANTICONVULSANTS/ ANTIEPILEPTICS |
Outras observações: For use as adjunctive therapy for treatment-resistant partial or generalized seizures. |
WHO Model List of Essential Medicines (2021) | 05. ANTICONVULSANTS/ ANTIEPILEPTICS |
Outras observações: For use as adjunctive therapy for treatment-resistant partial or generalized seizures. |
Listas | Seção | Observação |
---|---|---|
Training CSamouge 2022 | 5. ANTICONVULSANTS/ ANTIEPILEPTICS |
Outras observações: For use as adjunctive therapy for treatment-resistant partial or generalized seizures. |
WHO Model List of Essential Medicines (2021) | 05. ANTICONVULSANTS/ ANTIEPILEPTICS |
Outras observações: For use as adjunctive therapy for treatment-resistant partial or generalized seizures. |
Listas | Seção | Observação |
---|---|---|
Training CSamouge 2022 | 5. ANTICONVULSANTS/ ANTIEPILEPTICS |
Outras observações: For use as adjunctive therapy for treatment-resistant partial or generalized seizures. |
WHO Model List of Essential Medicines (2021) | 05. ANTICONVULSANTS/ ANTIEPILEPTICS |
Outras observações: For use as adjunctive therapy for treatment-resistant partial or generalized seizures. |
Listas | Seção | Observação |
---|---|---|
Training CSamouge 2022 | 5. ANTICONVULSANTS/ ANTIEPILEPTICS |
Outras observações: For use as adjunctive therapy for treatment-resistant partial or generalized seizures. |
WHO Model List of Essential Medicines (2021) | 05. ANTICONVULSANTS/ ANTIEPILEPTICS |
Outras observações: For use as adjunctive therapy for treatment-resistant partial or generalized seizures. |
Listas | Seção | Observação |
---|---|---|
Training CSamouge 2022 | 5. ANTICONVULSANTS/ ANTIEPILEPTICS |
Outras observações: For use as adjunctive therapy for treatment-resistant partial or generalized seizures. |
WHO Model List of Essential Medicines (2021) | 05. ANTICONVULSANTS/ ANTIEPILEPTICS |
Outras observações: For use as adjunctive therapy for treatment-resistant partial or generalized seizures. |